Exenatide mechanism of action

Exenatide is believed to facilitate glucose ascendancy in at atomic 5 ways:

Exenatide augments pancreas acknowledgment (i.e. increases insulin secretion) in acknowledgment to bistro meals; the aftereffect is the absolution of a higher, added adapted bulk of insulin that helps lower the acceleration in claret amoroso from eating. Once claret amoroso levels abatement afterpiece to accustomed values, the pancreas acknowledgment to aftermath insulin is reduced; added drugs (like injectable insulin) are able at blurred claret sugar, but can "overshoot" their ambition and could cause claret amoroso to become too low, consistent in the alarming action of hypoglycemia.

Exenatide aswell suppresses pancreatic absolution of glucagon in acknowledgment to eating, which helps stop the alarmist from overproducing amoroso if it is unneeded, which prevents hyperglycemia (high claret amoroso levels).

Exenatide helps apathetic down belly elimination and appropriately decreases the amount at which meal-derived glucose appears in the bloodstream.

Exenatide has a attenuate yet abiding aftereffect to abate appetite, advance abhorrence via hypothalamic receptors (different receptors than for amylin). A lot of humans application exenatide boring lose weight, and about the greatest weight accident is accomplished by humans who are the a lot of ample at the alpha of exenatide therapy. Clinical trials accept approved the weight abbreviation aftereffect continues at the aforementioned amount through 2.25 years of connected use. If afar into weight accident quartiles, the accomplished 25% acquaintance abundant weight loss, and the everyman 25% acquaintance no accident or baby weight gain.

Exenatide reduces alarmist fat content. Fat accession in the alarmist or nonalcoholic blubbery alarmist ache (NAFLD) is acerb accompanying with several metabolic disorders, in accurate low HDL cholesterol and top triglycerides, present in patients with blazon 2 diabetes. It became credible that exenatide bargain alarmist fat in mice and added afresh in man.

In an open-label, randomized, controlled balloon of 551 patients, exenatide analysis for 26 weeks was associated with 2.3 kg weight loss; however, gastrointestinal affection were added accepted in the exenatide group, including abhorrence (57.1%), airsickness (17.4%) and diarrhea (8.5%).